Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 17/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | TTK | P33981 | 1/20 | 0.32 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.32 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.32 |
| ▸ | CLK2 | P49760 | 1/20 | 0.32 |
| ▸ | CLK3 | P49761 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4174329 | 0.90 | LRRK2 (0.35) | LRRK2CYP3A4TTKAURKBINCENP | |
| SCHEMBL4084371 | 0.88 | LRRK2 (0.35) | LRRK2 | |
| SCHEMBL4179171 | 0.87 | CSNK1D (0.38) | LRRK2CLK2CLK3DYRK1A | |
| SCHEMBL4165501 | 0.86 | LRRK2 (0.35) | LRRK2CLK2CLK3DYRK1A | |
| SCHEMBL4175023 | 0.78 | MAPK8 (0.35) | CYP3A4TTKAURKBINCENPCLK2 | |
| SCHEMBL4314649 | 0.76 | CHRNB2 (0.45) | CLK2DYRK1A | |
| SCHEMBL4093565 | 0.76 | CHRNB2 (0.45) | CLK2DYRK1A | |
| SCHEMBL13812025 | 0.76 | CLK2 (0.39) | LRRK2TTKCLK2CLK3DYRK1A | |
| SCHEMBL4258020 | 0.76 | CHRNB2 (0.45) | CLK2DYRK1A | |
| SCHEMBL4079772 | 0.76 | ACHE (0.40) | LRRK2TTKCLK2DYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | BHAGWAT SHRIPAD S | 2009-04-16 | — | — | US | disclosed |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | BHAGWAT SHRIPAD S | 2006-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099178-A1 | INDAZOLE COMPOUNDS AND METHODS OF USE THEREOF | WNT3, WNT3A, WNK3 | LRRK2 553/4885CYP3A4 2529/4885TTK 401/4885 |
| US-20060004043-A1 | Indazole compounds and methods of use thereof | WNT3, WNT3A, WNK3 | LRRK2 563/4885CYP3A4 2646/4885TTK 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.